Compare IDEXX Laboratories, Inc. (IDXX) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs VICI Properties Inc — how do they compare? IDEXX Laboratories, Inc. trades at $558.25 (market cap $44.48B), while VICI Properties Inc trades at $26.56 (market cap $29.55B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and VICI Properties Inc pays a 6.71% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | VICI | |
|---|---|---|
Market Cap | $44.48B | $29.55B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $33.93 |
52-Week Low | $520.87 | $25.94 |
Enterprise Value | $45.38B | $46.77B |
Dividend Yield | — | 6.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
VICI Properties trades at $26.83, down 0.15% on the day, with technical indicators showing a neutral bias. The REIT maintains strong fundamentals with a 76.83% net income margin and consistent earnings beats in three of the last four quarters. Recent news highlights institutional buying interest and dividend sustainability discussions amid sector volatility.
VICI offers a compelling value proposition with a 6.7% dividend yield and 36% upside to the consensus price target of $30.00. Key risks include tenant concentration with Caesars/MGM accounting for 70% of rent and macroeconomic sensitivity. Wall Street remains bullish with 77% buy ratings supporting long-term income growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
